Related Experiment Videos
[Lipoprotein-associated phospholipase A2: importance and perspectives]
1Cattedra di Semeiotica Medica, Dipartimento di Medicina Interna, Università degli Studi di Pisa, Pisa. mcamici@tiscalinet.it
Minerva Medica
|July 24, 2004
Summary
Type VII phospholipase A2, an enzyme linked to low-density lipoproteins (LDL), is a novel risk factor for coronary disease. Inhibiting this enzyme may offer new atherosclerosis therapies and aid in acute coronary syndrome recognition.
Area of Science:
- Biochemistry
- Cardiology
- Enzymology
Background:
- Type VII phospholipase A2 (PLA2G7), also known as platelet-activating factor acetylhydrolase, is associated with low-density lipoproteins (LDL).
- Emerging evidence identifies PLA2G7 as a non-traditional, independent risk factor for coronary heart disease (CHD).
Purpose of the Study:
- To review current physiological and biochemical knowledge of LDL-associated Type VII phospholipase A2.
- To explore its role in lipoprotein metabolism and atherogenesis.
- To discuss future therapeutic strategies targeting this enzyme in atherosclerosis.
Main Methods:
- Literature review of recent physiological and biochemical studies on Type VII phospholipase A2.
- Analysis of the enzyme's role in lipoprotein metabolism and the development of atherosclerosis.
- Exploration of potential therapeutic interventions and diagnostic applications.
Main Results:
- Type VII phospholipase A2 plays a significant role in lipoprotein metabolism.
- The enzyme is implicated in the complex process of atherogenesis.
- Inhibitors of this enzyme show promise for atherosclerosis therapy.
Conclusions:
- Understanding Type VII phospholipase A2's function provides insights into atherosclerosis.
- Targeting this enzyme offers potential therapeutic avenues for cardiovascular disease.
- Measuring circulating PLA2G7 activity may aid in preventing and diagnosing acute coronary syndromes.